Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Annals of the Rheumatic Diseases|August 5, 2025
Chondrocalcinosis and incident knee osteoarthritis: findings from 2 large prospective cohorts with 20 years of follow-upYahong Wu, Jean W Liew, Justin D Boer, et al.
Materials Today. Bio|October 22, 2024
One arrow two eagles: Multifunctional nano-system for macrophage reprogramming and osteoclastogenesis inhibition against inflammatory osteolysisTong Sha, Ze Wang, Jinwei Li, et al.
Science China. Life Sciences|February 7, 2024
Hemin blocks TIGIT/PVR interaction and induces ferroptosis to elicit synergistic effects of cancer immunotherapyXiaowen Zhou, Yang Li, Xiangrui Zhang, et al.
Acta Pharmaceutica Sinica. B|November 16, 2023
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapyXiaoshuang Niu, Menghan Wu, Guodong Li, et al.
Neoplasia (New York, N.Y.)|June 24, 2025
Screening and identification of HLA-A2-restricted neoepitopes for immunotherapy in endocrine therapy-resistant breast cancerMingshuang Wang, Liwei Pang, Yingjie Sun, et al.
Acta Pharmaceutica Sinica. B|September 30, 2021
Tryptophan 2,3-dioxygenase 2 controls M2 macrophages polarization to promote esophageal squamous cell carcinoma progression <i>via</i> AKT/GSK3<i>β</i>/IL-8 signaling pathwayYumiao Zhao, Jiaxin Sun, Yin Li, et al.
Cell Communication and Signaling : CCS|March 11, 2024
Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapyShengzhe Jin, Hongfei Wang, Yang Li, et al.
Biochemical Pharmacology|May 6, 2023
Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapyMenghan Wu, Aijun Wu, Xiangrui Zhang, et al.
Cell Death & Disease|May 25, 2022
Dysfunction of the energy sensor NFE2L1 triggers uncontrollable AMPK signaling and glucose metabolism reprogrammingLu Qiu, Qiufang Yang, Wenshan Zhao, et al.
Journal for Immunotherapy of Cancer|November 2, 2022
Identification of natural product 3, 5-diiodotyrosine as APOBEC3B inhibitor to prevent somatic mutation accumulation and cancer progressionChunxia Chen, Xinghua Sui, Haoming Ning, et al.
Pageof 8